Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 133 participants.

Also called NCT02072161

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 133 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02072161
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02072161. Randomized; quadruple masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2015-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy
Condition
Hypercholesterolemia
Intervention (Drug)
ETC-1002
Intervention (Drug)
Placebo
Intervention (Drug)
Statin Therapy
Lead sponsor
Esperion Therapeutics, Inc. (class: industry)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02072161
Content hash
4a383ff87da275dacb5cd2968cc5d42216f72ad44ef2545ab0294511ad1a7ea6